Toronto - Delayed Quote CAD

Avicanna Inc. (AVCN.TO)

0.2800

-0.0300

(-9.68%)

At close: January 24 at 3:55:00 PM EST

Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma

Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in CanadaTORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that Avicanna has entered into a scientific and medical affairs collaboration agreement with Vectura

GlobeNewswire 9 days ago

AVCNF
Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company

Cosmetic registration and delivery into Germany completed in preparation for the initial commercial LaunchTORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the initial delivery of its proprietary topical products into Europe as a part of the previously announce

GlobeNewswire last month

AVCNF
Avicanna Third Quarter 2024 Earnings: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna ( TSE:AVCN ) Third Quarter 2024 Results Key Financial Results Revenue: CA$6.27m (flat on 3Q 2023). Net loss...

Simply Wall St. 2 months ago

AVCNF
Avicanna Reports Q3 2024

9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce results Q3 2024. “We are pleased to report the results of another quarter showing progr

GlobeNewswire 2 months ago

AVCNF
Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is

GlobeNewswire 2 months ago

AVCNF
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca

1000 patient study on impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy Study to be led by Dr. Hance Clarke President of The Canadian Pain Society and the CCICTORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce a large-scale medical cannabi

GlobeNewswire 4 months ago

AVCNF
Avicanna Announces Repayment of Debentures

TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce it has cleared and fully repaid $1,445,000 that was owed under the Debentures of August 2 2023. About Avicanna Inc. Avicanna is a commercial-stage international biopharmaceutical com

GlobeNewswire 4 months ago

AVCNF
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology

USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topicalcannabinoid composition and methods for treating musculoskeletal inflammation and pain TORONTO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the United States Patent and Trade

GlobeNewswire 4 months ago

AVCNF
Avicanna Second Quarter 2024 Earnings: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna ( TSE:AVCN ) Second Quarter 2024 Results Key Financial Results Revenue: CA$6.12m (up 85% from 2Q 2023). Net...

Simply Wall St. 5 months ago

AVCNF
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark

19th international market for Aureus branded products and 22nd market for all Avicanna productsTORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority-owned subsidiary Santa Marta Golden Hemp SAS, the Company has completed the commercial export of

GlobeNewswire 5 months ago

AVCNF
Avicanna Reports Q2 2024

Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products reports the results of Q2 2024. “We are happy to deliver another progressive quarter

GlobeNewswire 5 months ago

AVCNF
Avicanna Announces Changes of Auditors

TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products announces a change of auditors from Kingston Ross Pasnak LLP (“Former Auditor”) to Ramirez Jimenez International CPAs (“Successor Auditor”) effective August 2, 2024 until the next Annual General Meeting of Shareholders of the Company. Ther

GlobeNewswire 5 months ago

AVCNF
OTC Markets Hosts Virtual Investor Presentation with Aras Azadian, CEO of Avicanna Inc., and Brad Sorensen, Senior Analyst at Zacks SCR

OTCQX:AVCNF | TSX:AVCN Anthony Kraus: Hello and welcome to Virtual Investor Conferences. My name is Anthony Kraus and on behalf of OTC Markets as well as our co-host Zacks Small Cap Research, we're very pleased you have joined us for our next live presentation from Avicanna Inc. Their session will be moderated by Brad Sorensen, CFA, Senior Equity Research Analyst with Zacks Small Cap Research.

Zacks Small Cap Research 6 months ago

AVCNF
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore

This marks the first export into Asia, the 18th international market for Aureus branded products and 21st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority-owned subsidiary Santa Marta Golden Hemp the Compan

GlobeNewswire 6 months ago

AVCNF
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update

TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s Management Information Circular dated May 31, 2024 (“Circular”) were elected as directors of the Company at the Company’s Annual General Meeting of Sharehold

GlobeNewswire 6 months ago

AVCNF
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4cbVF5U The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download in

GlobeNewswire 7 months ago

LGVN

LGVNR

GLABF
Avicanna General Meeting

Annual General Meeting will be on July 10, 2024TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that as previously disclosed its annual general meeting will be held virtually on Wednesday, July 10, 2024 at 10:30 AM (Toronto Time) (“Meeting”). The Toronto Stock exch

GlobeNewswire 7 months ago

AVCNF
Avicanna Announces USPTO Issuance of Patent SEDDS Technology

Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna’s self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of treating neuropathic painTORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the United States Patent and Trademark Offi

GlobeNewswire 7 months ago

AVCNF
Life Sciences Virtual Investor Forum Agenda Announced for June 20th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20th, 2024. This event is co-sponsored by Zack’s Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4bUev

GlobeNewswire 7 months ago

GLABF

BBLG

BBLGW
Avicanna to Present at the Life Science Investor Forum June 20th, 2024

Investors, advisors and analysts, will have the opportunity to attend in-person or participate online at VirtualInvestorConferences.comTORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce Aras Azadian CEO of Avicanna will be delivering a presentation live at the Life Scien

GlobeNewswire 7 months ago

AVCNF

Performance Overview

Return	AVCN.TO	S&P/TSX Composite index
YTD	-6.67%	+3.44%
1-Year	-11.11%	+21.08%
3-Year	-42.86%	+23.51%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avicanna Inc. (AVCN.TO)

Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma

Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company

Avicanna Third Quarter 2024 Earnings: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna Reports Q3 2024

Avicanna Announces Closing of Non-Brokered Private Placement

Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca

Avicanna Announces Repayment of Debentures

Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology

Avicanna Second Quarter 2024 Earnings: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark

Avicanna Reports Q2 2024

Avicanna Announces Changes of Auditors

OTC Markets Hosts Virtual Investor Presentation with Aras Azadian, CEO of Avicanna Inc., and Brad Sorensen, Senior Analyst at Zacks SCR

Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore

Avicanna Announces Results of Annual General Meeting & Provides Corporate Update

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Avicanna General Meeting

Avicanna Announces USPTO Issuance of Patent SEDDS Technology

Life Sciences Virtual Investor Forum Agenda Announced for June 20th

Avicanna to Present at the Life Science Investor Forum June 20th, 2024

Performance Overview